Latest News for SHIEF
Shield Therapeutics plc (SHIEF) Q1 2026 Sales/Trading Call Transcript
Shares in Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) fell 12% to 7.71p after the group reported first-quarter revenue growth and positive earnings but...
Shares in Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) fell 12% to 7.71p after the group reported first-quarter revenue growth and positive earnings but flagged potential headwinds in the US market and announced the departure of its finance chief. The pharmaceutical company, which focuses on iron deficiency treatments, said group net revenues rose to $18 million in the quarter, up from $7 million a year earlier,…
Broker Cavendish says additional US protection strengthens long-term outlook and reiterates buy rating. Shares in Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) jumped as much 11% earlier in the session after the company said US regulators had granted an additional three years of data exclusivity for its oral iron therapy Accrufer.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for SHIEF.
Senate Trading
No Senate trades found for SHIEF.
U.S. House Trading
No House trades found for SHIEF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.